Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
35 studies found for:    EGFRvIII
Show Display Options
Rank Status Study
1 Recruiting EGFRvIII CAR T Cells for Newly-Diagnosed GBM
Condition: Glioblastoma
Intervention: Biological: EGFRvIII CAR T cells
2 Recruiting Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Biological: anti-EGFRvIII CAR T cells;   Drug: cyclophosphamide;   Drug: Fludarabine
3 Active, not recruiting Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
Condition: Patients With Residual or Reccurent EGFRvIII+ Glioma
Intervention: Biological: CART-EGFRvIII T cells
4 Recruiting CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Conditions: Malignant Glioma;   Glioblastoma;   Brain Cancer
Interventions: Biological: Anti-EGFRvIII CAR transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
5 Recruiting Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
Condition: Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
Intervention:
6 Active, not recruiting Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Conditions: Glioblastoma;   Brain Tumor, Recurrent
Intervention: Drug: PF-299804 (Dacomitinib)
7 Completed A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
8 Recruiting The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma
Condition: Glioma
Intervention: Diagnostic Test: 89Zr-ABT806 PET
9 Terminated Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
Conditions: Brain Cancer;   Brain Stem Tumors;   Pontine Tumors
Intervention: Biological: Rindopepimut
10 Completed AMG 595 First-in-Human in Recurrent Gliomas
Conditions: Advanced Malignant Glioma;   Anaplastic Astrocytomas;   Glioblastoma Multiforme
Intervention: Drug: AMG 595
11 Terminated S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Conditions: Brain Tumors;   Gastric Cancer;   Ovarian Cancer;   Prostate Cancer
Interventions: Biological: KLH;   Biological: GMCSF
12 Completed Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
13 Completed
Has Results
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3 vaccine;   Biological: sargramostim;   Drug: Temozolomide
14 Recruiting The Addition of Chloroquine to Chemoradiation for Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: Chloroquine;   Radiation: Radiotherapy;   Drug: Temozolomide
15 Completed Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
Condition: Malignant Glioma
Interventions: Drug: CDX-110 with GM-CSF;   Drug: Temozolomide
16 Recruiting D2C7 for Adult Patients With Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Brain Tumor, Recurrent
Intervention: Drug: D2C7-IT
17 Recruiting Phase I Study of Safety and Immunogenicity of ADU-623
Conditions: Astrocytic Tumors;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Brain Tumor
Interventions: Biological: Cohort 1;   Biological: Cohort 2;   Biological: Cohort 3;   Drug: Antibiotics
18 Not yet recruiting The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Conditions: Glioblastoma;   Astrocytoma, Grade IV
Intervention: Drug: Chloroquine
19 Completed Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: daclizumab;   Drug: temozolomide;   Other: placebo;   Biological: PEP-3-KLH
20 Completed
Has Results
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.